why choose us

First received: July 25, 2024

Clinical Trial: A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A First-in-human Open Label Phase Ia/Ib, Multicenter/Multiregional, Dose Escalation Study of BI 765883 Administered Intravenously as Monotherapy and in Combination With Gemcitabine and Nab-p

Brief Summary: This study is open to adults with advanced pancreatic cancer for whom previous treatment was not successful or no treatment exists.The purpose of this study is to find the highest dose of BI 765883 that people with advanced pancreatic cancer can tolerate when taken alone or together with chemotherapy.Another purpose is to check whether BI 765883 helps people with advanced pancreatic cancer.In this study, BI 765883 is given to humans for the first time.Participants receive either BI 765883 alone or BI 765883 in…

Read more